{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:25:58Z","timestamp":1789961158458,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of abatacept treatment for refractory juvenile localized scleroderma (jLS) in a retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre cohort study was performed to evaluate jLS subjects treated with abatacept with follow-up for 12\u2009months to maximum of 24\u2009months. Assessments at 6-month intervals included skin activity measures and physician global assessment of activity (PGA-A). Descriptive statistical analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen subjects were studied with median age of 13.4\u2009years, the majority had linear scleroderma subtype, and musculoskeletal involvement. All had previously failed MTX and\/or mycophenolate mofetil treatment and glucocorticoids. Abatacept was added to the subject\u2019s maintenance DMARD treatment; 13 also received glucocorticoids at start of abatacept. No serious adverse events occurred. Skin activity and PGA-A scores declined in nearly all by 6\u2009months and continued to improve from 6 to 12\u2009months. At 12\u2009months, 15 (83%) subjects were considered responders, two (11%) treatment failures, and one dropped out for adverse event. Response was sustained for 11 (61%) subjects to 18\u2009months and eight (44%) to 24\u2009months. Overall, four (22%) subjects were treatment failures and three (16.7%) discontinued abatacept for adverse event. Active musculoskeletal problems improved in most affected subjects. Ten subjects were able to discontinue initial glucocorticoid and six concomitant DMARD treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Abatacept was found to be safe and effective for jLS subjects refractory to standard of care treatment. Subjects experienced improvement in both skin and musculoskeletal activity. Prospective studies should be performed to more fully evaluate abatacept\u2019s efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa873","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T22:55:56Z","timestamp":1607468156000},"page":"3817-3825","source":"Crossref","is-referenced-by-count":31,"title":["Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-2866","authenticated-orcid":false,"given":"Suzanne C","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Joseph M. Sanzari Children\u2019s Hospital, Hackensack University Medical Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S","family":"Torok","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S","family":"Ishaq","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Montclair State University, Montclair, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Buckley","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke Children\u2019s Hospital and Health Center, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Edelheit","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Connecticut Children\u2019s Medical Center, Hartford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleo C","family":"Ede","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Phoenix Children\u2019s Hospital, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Montclair State University, Montclair, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Egla","family":"Rabinovich","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke Children\u2019s Hospital and Health Center, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"2021080220003206000_keaa873-B1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/acr.23101","article-title":"Predictors of longitudinal quality of life in juvenile localized scleroderma","volume":"69","author":"Ardalan","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021080220003206000_keaa873-B2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/art.21264","article-title":"Localized scleroderma in childhood is not just a skin disease","volume":"52","author":"Zulian","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021080220003206000_keaa873-B3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.1019","article-title":"Baseline description of the juvenile localized scleroderma subgroup from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry","volume":"1","author":"Wu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2021080220003206000_keaa873-B4","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1212\/01.wnl.0000334474.88923.e3","article-title":"Neurologic manifestations of localized scleroderma. A case report and literature review","volume":"71","author":"Kister","year":"2008","journal-title":"Neurology"},{"key":"2021080220003206000_keaa873-B5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/pde.13336","article-title":"Orthopedic complications of linear morphea: implications for early interdisciplinary care","volume":"35","author":"Schoch","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"2021080220003206000_keaa873-B6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021080220003206000_keaa873-B7","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021080220003206000_keaa873-B8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12969-018-0295-0","article-title":"Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management","volume":"16","author":"Lythgoe","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"2021080220003206000_keaa873-B9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3899\/jrheum.190311","article-title":"Initial results from a pilot comparative effectiveness study of 3 methotrexate-based consensus treatment plans for juvenile localized scleroderma","volume":"47","author":"Li","year":"2020","journal-title":"J Rheumatol"},{"key":"2021080220003206000_keaa873-B10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","article-title":"Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology"},{"key":"2021080220003206000_keaa873-B11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2340\/00015555-2297","article-title":"Use of mycophenolate mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2021080220003206000_keaa873-B12","article-title":"Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma","author":"Martini","journal-title":"Rheumatology (Oxford)"},{"key":"2021080220003206000_keaa873-B13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamadermatol.2020.0035","article-title":"Evaluation of the effectiveness and tolerability of mycophenolate mofetil and mycophenolic acid for the treatment of morphea","volume":"156","author":"Arthur","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2021080220003206000_keaa873-B14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/18743129014090100030","article-title":"A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide","volume":"9","author":"Ferguson","year":"2015","journal-title":"Open Rheumatol J"},{"key":"2021080220003206000_keaa873-B15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5301\/jsrd.5000259","article-title":"Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients","volume":"2","author":"Foeldvari","year":"2017","journal-title":"J Scleroderma and Relat Dis"},{"key":"2021080220003206000_keaa873-B16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology"},{"key":"2021080220003206000_keaa873-B17","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?","volume":"35(Suppl 106","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2021080220003206000_keaa873-B18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fimmu.2019.00908","article-title":"Immunopathogenesis of pediatric localized scleroderma","volume":"10","author":"Torok","year":"2019","journal-title":"Front Immunol"},{"key":"2021080220003206000_keaa873-B19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jid.2018.09.025","article-title":"Identifying the signature immune phenotypes present in pediatric localized scleroderma","volume":"139","author":"Mirizio","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2021080220003206000_keaa873-B20","doi-asserted-by":"crossref","first-page":"R188","DOI":"10.1186\/ar4378","article-title":"Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma","volume":"15","author":"Magee","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021080220003206000_keaa873-B21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","article-title":"Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokines profiles","volume":"45","author":"Torok","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220003206000_keaa873-B22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia)","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220003206000_keaa873-B23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2340\/00015555-1136","article-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases","volume":"91","author":"Stausb\u00f8l-Gr\u00f8n","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"2021080220003206000_keaa873-B24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/00015555-2878","article-title":"Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series","volume":"98","author":"Fage","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2021080220003206000_keaa873-B25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: a pediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220003206000_keaa873-B26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"2021080220003206000_keaa873-B27","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3899\/jrheum.081284","article-title":"The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures","volume":"36","author":"Arkachaisri","year":"2009","journal-title":"J Rheumatol"},{"key":"2021080220003206000_keaa873-B28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.110210","article-title":"Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study","volume":"39","author":"Torok","year":"2012","journal-title":"J Rheumatol"},{"key":"2021080220003206000_keaa873-B29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021080220003206000_keaa873-B30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.171381","article-title":"New features for measuring disease activity in pediatric localized scleroderma","volume":"45","author":"Li","year":"2018","journal-title":"J Rheumatol"},{"key":"2021080220003206000_keaa873-B31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","article-title":"Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study","volume":"49","author":"Arkachaisri","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021080220003206000_keaa873-B32","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021080220003206000_keaa873-B33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaa873\/35199483\/keaa873.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3817\/39543483\/keaa873.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3817\/39543483\/keaa873.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T15:09:36Z","timestamp":1723993776000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3817\/6053808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,12,28]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa873","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,12,28]]}}}